Vimentin Overexpressions Induced by Cell Hypoxia Promote Vasculogenic Mimicry by Renal Cell Carcinoma Cells

Down-regulating Myoferlin inhibits the vasculogenic mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition

(2017) Wenxue Zhang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment

(2017) Meili Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeted therapies for renal cell carcinoma

(2017) Edwin M. Posadas et al.   Nature Reviews Nephrology

Renal cell carcinoma

(2017) James J. Hsieh et al.   Nature Reviews Disease Primers

The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment

(2016) Shuixian Li et al.   BIOMEDICINE & PHARMACOTHERAPY

Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis

(2016) L.-Y. Ye et al.   CANCER RESEARCH

The relationship between vasculogenic mimicry and epithelial-mesenchymal transitions

(2016) Qiqi Liu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Hypoxic control of metastasis

(2016) E. B. Rankin et al.   SCIENCE

Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study

(2016) A. Ingels et al.   WORLD JOURNAL OF UROLOGY

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib

(2016) Maria Serova et al.   Oncotarget

Systemic Therapy for Non–clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis

(2015) Francisco E. Vera-Badillo et al.   EUROPEAN UROLOGY

A river model to map convergent cancer evolution and guide therapy in RCC

(2015) Elizabeth Y. Wei et al.   Nature Reviews Urology

DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma

(2015) Wei Zhao et al.   PATHOLOGY RESEARCH AND PRACTICE

Matrix metalloproteinase-9 is required for vasculogenic mimicry by clear cell renal carcinoma cells

(2015) Hao Lin et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer

(2014) Rui-Jun Ju et al.   BIOMATERIALS

Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53

(2014) Z.-G. Shi et al.   Clinical & Translational Oncology

Hypoxia promotes vasculogenic mimicry formation by inducing epithelial–mesenchymal transition in ovarian carcinoma

(2014) Jing Du et al.   GYNECOLOGIC ONCOLOGY

Renal cell carcinoma

(2014) E. Jonasch et al.   BMJ-British Medical Journal

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

(2013) Nils Kroeger et al.   CANCER

Tumor Cell Vasculogenic Mimicry

(2012) Richard E.B. Seftor et al.   AMERICAN JOURNAL OF PATHOLOGY

Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis

(2012) Yuan Xu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells

(2012) P. B. Makhov et al.   MOLECULAR CANCER THERAPEUTICS

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma

(2010) Hélène Marijon et al.   JOURNAL OF HEPATOLOGY

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib

(2010) J C Welti et al.   ONCOGENE

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer

(2010) K Vuoriluoto et al.   ONCOGENE

Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies

(2010) Guy Lahat et al.   PLoS One

Guideline for Management of the Clinical T1 Renal Mass

(2009) Steven C. Campbell et al.   JOURNAL OF UROLOGY

Mechanisms of adaptive angiogenesis to tissue hypoxia

(2008) Guo-Hua Fong   ANGIOGENESIS

Silibinin Inhibits Established Prostate Tumor Growth, Progression, Invasion, and Metastasis and Suppresses Tumor Angiogenesis and Epithelial-Mesenchymal Transition in Transgenic Adenocarcinoma of the Mouse Prostate Model Mice

(2008) R. P. Singh et al.   CLINICAL CANCER RESEARCH